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Diagnosis of Arrhythmogenic CardioMyopathy (ACM) is challenging and often late after disease onset. 
No circulating biomarkers are available to date. Given their involvement in several cardiovascular 
diseases, plasma microRNAs warranted investigation as potential non-invasive diagnostic tools in ACM. 
We sought to identify circulating microRNAs differentially expressed in ACM with respect to Healthy 
Controls (HC) and Idiopathic Ventricular Tachycardia patients (IVT), often in differential diagnosis. 
ACM and HC subjects were screened for plasmatic expression of 377 microRNAs and validation was 
performed in 36 ACM, 53 HC, 21 IVT. Variable importance in data partition was estimated through 
Random Forest analysis and accuracy by Receiver Operating Curves. Plasmatic miR-320a showed 
0.53 ± 0.04 fold expression difference in ACM vs. HC (p < 0.01). A similar trend was observed when 
comparing ACM (n = 13) and HC (n = 17) with athletic lifestyle, a ACM precipitating factor. Importantly, 
ACM patients miR-320a showed 0.78 ± 0.05 fold expression change vs. IVT (p = 0.03). When compared 
to non-invasive ACM diagnostic parameters, miR-320a ranked highly in discriminating ACM vs. IVT and 
it increased their accuracy. Finally, miR-320a expression did not correlate with ACM severity. Our data 
suggest that miR-320a may be considered a novel potential biomarker of ACM, specifically useful in 
ACM vs. IVT differentiation.
Arrhythmogenic CardioMyopathy (ACM) is a genetic disease characterized by a progressive fibro-fatty sub-
stitution of the ventricular myocardium, particularly pronounced in the right ventricle (RV), associated with 
life-threatening ventricular arrhythmias and heart failure (HF). With an estimated prevalence ranging from 
1:2000 to 1:5000, ACM affects men more frequently than women1, representing one of the most diffuse cause of 
sudden death in young athletes2. Up to 50% of individuals with ACM harbour an autosomal dominant mutation 
in one of the genes coding for cardiac desmosome components3. Desmosomes are complex cellular junctions 
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with structural and intracellular signalling functions, mediated by the WNT/β-catenin pathway4, which is a key 
regulator of cardiac development, response to injury5, and cell fate6.
The diagnosis of ACM is challenging and often late after disease onset because of the broad spectrum of phe-
notypic presentations. Currently, no single gold standard diagnostic method is available. Even the identification 
of an associated genetic defect, when possible, may be not conclusive because of the high variability in penetrance 
and expressivity. According to the International Task Force recommendations, the decision-making process relies 
on a scoring system of major and minor criteria, including clinical, instrumental and genetic tests. ACM is ascer-
tained in the presence of either two major, one major plus two minor, or four minor criteria7. Importantly, using 
non-invasive tools only (e.g. Fig. 1), a conclusive diagnosis is not reached in a substantial number of patients. 
Invasive procedures such as endomyocardial biopsy and/or electroanatomic mapping may be needed to confirm 
the presence of the disease8, 9.
Particularly challenging is also the differential diagnosis for ACM, which includes Idiopathic Ventricular 
Tachycardia (IVT), a primary electrical cardiac condition with a similar arrhythmic phenotype. The two entities 
share several phenotypic similarities: left bundle branch block with inferior axis ventricular tachycardia, symp-
toms aggravation after exercise, predominant occurrence in young, otherwise healthy individuals. Nonetheless, 
while ACM is a life-threatening disease, IVT has a more favourable outcome and different therapeutic options10. 
Thus, early and definite distinction between ACM and IVT is of the upmost clinical importance. As a conse-
quence, novel ACM early diagnostic biomarkers are currently under investigation. The plakoglobin mislocaliza-
tion assay is a promising candidate as a new diagnostic tool11, however it is exploitable only in bioptic or autoptic 
samples only. Plasma BIN1 has recently been proposed as predictor of arrhythmias in ACM, although restricted 
to subjects presenting symptomatic HF12.
In the last few years microRNAs (miRNAs), short (22–24 nucleotides) non-coding RNAs, have been found 
to be stably expressed in the systemic circulation of both animals and humans13. Notably, several reports from 
others and our laboratory described the diagnostic potential of circulating miRNAs in different heart conditions, 
including myocardial infarction14, HF15 and atrial fibrillation16.
No previous study has evaluated circulating miRNAs as potential biomarkers of ACM. In the present work, 
we assessed miRNAs expression in plasma samples obtained from ACM and NON-ACM subjects. Our results 
indicate that miR-320a is significantly less expressed in ACM patients’ plasma and that it may be helpful in dif-
ferentiating ACM from IVT.
Figure 1. Non-invasive diagnostic tests in an Arrhythmogenic CardioMyopathy (ACM) patient. (A) Baseline 
12-lead ECG shows regular sinus rhythm with inverted T waves in the precordial leads from V1 to V4. (B) Four-
chamber echocardiographic imaging shows enlarged right ventricular diastolic volumes. Cardiac magnetic 
resonance: four-chamber short-axis (C) and long axis (D) images reveal dilated right ventricle with segmental 
kinesis abnormalities, mainly involving the inferolateral wall.
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Methods
Ethical statement. This study complies with the Declaration of Helsinki and was approved by the Ethics 
Committees of Centro Cardiologico Monzino (06/06/2012), Centro Cardiovascolare dell’Azienda Ospedaliera 
Universitaria di Trieste (Project Number: N.O.43/2009, prot.2161) and Dipartimento di Neuroscienze, 
Biomedicina e Movimento, Università degli Studi di Verona (March, 30/03/2012, #99). Written informed consent 
was obtained from all participants.
Study population. A total of 110 male subjects were enrolled in three independent recruiting centres: 53 
healthy controls (HC), 36 patients affected by ACM and 21 patients affected by IVT. Baseline characteristics of the 
different cohorts of patients are reported in Tables 1 and 2 and Supplementary Tables S1, S2 and S3.
HC without previous history of heart disease, age- and sex-matched with ACM patients have been selected. 
Healthy long-distance runners, classified in group D of cardiovascular risk according to the COCIS score17, were 
classified as HC athletes. Blood samples were withdrawn in a resting period.
ACM diagnosis was reached according to the International Task Force criteria7. Among ACM patients, 13 
subjects were classified in group D of cardiovascular risk17 and defined as ACM-athletes for comparison with HC 
athletes.
IVT patients were characterized by right or left ventricular outflow tract tachycardia in the absence of any 
sign of structural heart disease18 as documented by 2D-echocardiography, magnetic resonance and/or electroan-
atomic mapping9.
BNP assay. Brain Natriuretic Peptide plasma levels were analysed using the BNP ARCHITECT chemilu-
minescent microparticle immunoassay on the ARCHITECT i2000 System (Abbott Diagnostics), following the 
manufacturer’s instructions.
Electroanatomic Mapping. Electroanatomic mapping of the RV was performed using CARTO system 
(Biosense Webster). At least 150 mapping points were sampled with an irrigated-tip Navi-Star catheter (Biosense 
HC IVT ACM
p HC vs. 
ACM
p IVT vs. 
ACM
N 53 21 36 — —
Age (years) 42.88 ± 1.57 48.05 ± 3.09 48.39 ± 2.22 0.07 0.96
Male gender n (%) 53 (100) 21 (100) 36 (100) — —
BMI 24.36 ± 0.35 24.40 ± 0.43 24.39 ± 0.43 0.95 0.26
Table 1. Baseline characteristics of enrolled subjects. HC, Healthy Control subjects; IVT, patients affected by 
Idiopathic Ventricular Tachycardia; ACM, patients affected by Arrhythmogenic CardioMyopathy; BMI, Body 
Mass Index.
IVT ACM p IVT vs. ACM
Global or regional dysfunction and 
structural alteration n (%)
Minor 2 (9.52) 12 (33.33) 0.04
Major 0 (0) 18 (50) <0.01
Tissue characterization n (%)
Minor — 2 (8.69) —
Major — 12 (52.17) —
Repolarization abnormalities n (%)
Minor 4 (0.19) 9 (0.25) 0.61
Major 1 (0.05) 17 (0.47) <0.01
Depolarization abnormalities n (%)
Minor 0 (0) 8 (22.22) 0.02
Major 0 (0) 10 (27.78) <0.01
Arrhythmias n (%)
Minor 21 (100) 15 (41.67) <0.01
Major 0 (0) 17 (47.22) <0.01
Family history n (%)
Minor 0 (0) 4 (11.11) 0.11
Major 0 (0) 8 (22.22) 0.02
LVEF (%) 58.85 ± 1.29 58.55 ± 1.75 0.91
TAPSE (mm) 24.72 ± 0.93 19.94 ± 0.83 <0.01
MAE n (%) 2 (9.52) 24 (66.67) <0.01
BNP (pg/ml) 21.88 ± 3.11 46.85 ± 8.34 0.15
miR-320a (relative expression) 1 ± 0.10 0.78 ± 0.05 0.03
Table 2. Established Arrhythmogenic CardioMyopathy (ACM) major or minor diagnostic criteria7 and clinical 
characteristics in Idiopathic Ventricular Tachycardia (IVT) vs. ACM patients. LVEF, Left Ventricular Ejection 
Fraction (n = 21 IVT, n = 35 ACM); TAPSE, Tricuspid Annular Plane Systolic Excursion (n = 18 IVT, n = 35 
ACM); MAE, Prior Major Arrhythmic Events (n = 21 IVT, n = 36 ACM); BNP, Brain Natriuretic Peptide 
(n = 20 IVT, n = 32 ACM).
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Webster). Bipolar and unipolar electrograms were analysed. Reference values for identifying normal endocardial 
bipolar and unipolar signals were defined as >1.5 and >5.5 mV, respectively.
2D-Echocardiography. 2D-echocardiography studies were performed with an iE33 system (Philips Medical 
Systems) using the S5-1 sector array probe. Complete standard 2D-echocardiography was performed according 
to clinical practice. In particular, biplane left ventricular ejection fraction (LVEF) was measured from apical 
4-chamber and 2-chamber views by the area-length method. From the 4-chamber apical view, the M-mode cur-
sor was positioned at the junction of the tricuspid valve plane with the RV free wall to evaluate tricuspid annular 
plane systolic excursion (TAPSE), defined as the difference in the displacement of the RV base from end-diastole 
to end-systole and used as an index of RV function19.
Magnetic Resonance. Patients were evaluated in a 1.5-T scanner (Discovery MR450; GE Healthcare). CMR 
data sets were analysed with a dedicated software (Report Card 4.0; GE Healthcare) as previously described20.
Plasma and RNA preparation. Blood samples (5 ml) were collected in EDTA coated tubes and centrifuged 
at 1500 × g for 15 min. Supernatants were collected, centrifuged again at 16000 × g for 15 min to obtain cells- and 
platelet-free plasma, and stored at −80 °C as 400 µl aliquots until usage.
Total RNA was extracted from plasma as previously described21. Briefly, 1 ml of TRIzol reagent (Life 
Technologies) was used for each 400 µl of plasma followed by phase separation and RNA precipitation with 1 ml 
of isopropanol after addition of 30 μg of glycogen (Roche). RNA pellets were obtained by centrifugation, washed 
with 1 ml of 70% ethanol, and centrifuged again for 10 min at 12.000 × g. Supernatants were discarded and pellets 
were resuspended in RNase-free water.
miRNA Screening. TaqMan Human microRNA Card A Arrays version 2.0 (Life Technologies) were used 
for expression screening of 377 miRNAs, using 3 µl of total RNA from 3 ACM and 3 HC subjects. Reverse tran-
scription (RT) and pre-amplification steps were performed according to the manufacturer’s protocol. Data were 
analysed with the ExpressionSuite software v1.0.3 (Life Technologies), normalized by the Global Normalization 
method. All miRNAs presenting a Ct ≥ 35 were considered as not expressed. miRNAs whose expression in ACM 
patients consistently (t-test p < 0.05) differed from controls more than 2-folds were considered for the validation 
phase.
miRNA expression analysis. The expression of each single miRNA was evaluated using TaqMan 
microRNA assays (Life Technologies) following manufacturer’s instructions. No RNA quantification was pos-
sible neither by spectrophotometric methods nor by using 2100 Bioanalyzer (Agilent Technologies). Therefore, 
the same volume of RNA (2 µl) was used in the RT step for technical consistency. As previously described14, 22–24 
we used an internal reference, so that all subsequent calculations were independent from RNA input. We selected 
3 miRNAs, basing on screening data analysis (miR-210, miR-375) and on previous reports24 (miR-16) for vali-
dation in all samples as potential references. Our results showed high intra-group data variability in all groups 
when using miR-16. Similarly, data obtained using miR-375 showed a less than optimal expression stability, as it 
was undetectable in a few samples. Conversely, miR-210 showed a strong expression in all samples with very lim-
ited intra-group variability when used for normalization. In addition, we confirmed, using NormFinder (http://
moma.dk/normfinder-software) that miR-210 has the lowest intra group variability and the best stability value 
(data not shown). Thus, miR-210 was selected as reference miRNA. The 2−ΔΔCt method was used to calculate 
miRNA expression relative to the mean expression of a calibrator group, indicated for each comparison.
Statistical Analysis. Continuous variables are presented as mean ± SEM, when not differently indicated. 
Comparisons between classes were performed by either parametric (One-way ANOVA, t-test) or non-parametric 
(Kruskal-Wallis, Mann-Whitney) tests, after assessment of the normality of the data by Kolmogorov-Smirnov 
test. Categorical variables are reported as frequencies and compared by Fisher’s exact test. The Random Forests 
method25 was used to rank the importance of selected variables in classifying ACM vs. IVT, by constructing 
multiple decision trees, bootstrapping 70% of samples 100 times. The mean decrease in Gini index was used as 
measure of the variable importance: Gini index measures the divergences between the probability distributions 
of the variable values. Therefore, variables with higher mean decrease in Gini index are more important for clas-
sification of the samples. The area under the curve (AUC) of Receiver Operating Characteristic (ROC) plots was 
used to assess diagnostic accuracy of selected variables: each plot shows the mean curve of 100 reiterated analyses 
through different bootstrap sampling of training and test sets. Correlation of miR-320a expression with clinical 
variables was calculated and reported as Spearman rho (ρ).
A two tailed p-value ≤ 0.05 was considered significant. Statistical analysis was performed using GraphPad 
Prism5 (GraphPad Software), and randomForest (v. 4.6–12) and ROCR (v.1.0–7) packages in R (v 3.3.0) 
environment.
Data Availability. The datasets generated and analysed during the current study are available from the cor-
responding authors on request. In particular, the raw data generated by the screening can be analysed using the 
dedicated free online tool (http://www.thermofisher.com/it/en/home/cloud.html).
Results
miR-320a expression in Arrhythmogenic CardioMyopathy patients and Healthy Controls. We 
conducted a screening of expression of 377 miRNAs in plasma samples from 3 symptomatic ACM patients and 
3 age- and sex-matched healthy donors. 121 miRNAs were detectable in all screened plasma samples and 5 miR-
NAs showed a potential differential expression (see Supplementary Table S4). We then tested their expression by 
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RT-qPCR in the whole cohort of ACM patients and HC (n = 36 and n = 53, respectively; baseline characteristics 
of the study groups are reported in Table 1). Only miR-320a showed a statistically significant lower expression in 
ACM patients with respect to HC (0.53 ± 0.04 and 1.00 ± 0.11, respectively, p < 0.01; Fig. 2).
Assessment of athletic status influence on miR-320a expression. Since 13 out of 36 ACM patients 
in our cohort were athletes (36.11%), and strenuous physical activity is considered a precipitating factor for the 
development of the disease26, we compared their miR-320a plasmatic expression with the sub-populations of HC 
athletes (n = 17; 32.07%), and these two subgroups with the non-athletic counterparts (the baseline character-
istics of the four subgroups are reported in Tables S1 and S2). As depicted in Fig. 3, no difference was observed 
between non-athlete and athlete subgroups both in HC (1.00 ± 0.22 vs. 1.16 ± 0.13, respectively; p = 0.10) and 
ACM patients (0.57 ± 0.04 vs. 0.55 ± 0.07, respectively; p = 0.60). On the contrary, the lower plasmatic expression 
of miR-320a in ACM vs. HC was confirmed both in non-athlete (p = 0.05) and athlete (p < 0.01) subgroups.
miR-320a expression in Arrhythmogenic CardioMyopathy and Idiopathic Ventricular 
Tachycardia patients. To ascertain its potential benefit in differential diagnosis, plasma miR-320a expres-
sion was compared in ACM (n = 36) vs. IVT (n = 21) patients. As presented in Fig. 4, ACM patients showed sig-
nificantly lower plasma levels of miR-320a than IVT patients (0.79 ± 0.05 fold; p = 0.03). Baseline characteristics 
of patient groups are described in Table 1, clinical and pathological features are reported in Table 2 and Table S3.
Ranking of non-invasive variables discriminating between Arrhythmogenic CardioMyopathy 
and Idiopathic Ventricular Tachycardia. To evaluate the performance of miR-320a in partitioning ACM 
vs. IVT patients, we used Random Forest learning method, considering substantial non-invasive variables that 
can be used to distinguish the two populations (Table 2). As shown in Fig. 5A, compared to each non-invasive 
parameter currently used to identify ACM patients (i.e. diagnostic criteria7), miR-320a showed a mean decrease 
in Gini Index value of 2.72[2.43–3.12] (median[Q1–Q3]), ranking second only to global/regional dysfunction 
and structural alteration 5.76[5.40–6.39], suggesting a higher classification potential than other well-known 
clinical criteria, in our cohort. ROC curve analyses (Fig. 5B) showed a moderate discriminating capacity of 
miR-320a alone (AUC = 0.69) and a slight increase in ACM prediction when miR-320a was added to global/
Figure 2. miR-320a shows a lower plasma expression in Arrhythmogenic CardioMyopathy (ACM) patients 
when compared to Healthy Controls (HC). Relative expression of plasma miR-320a in ACM patients (n = 36) 
with respect to HC (n = 53); the mean expression value in HC was arbitrarily set to one (HC 1.00 ± 0.11; ACM 
0.53 ± 0.04; p < 0.01, t-test).
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regional dysfunction criterion (AUC = 0.89 and 0.92, respectively) or to ECG abnormalities (AUC = 0.84 and 
0.88, respectively).
Similarly, as shown in Fig. S1, miR-320a presented a mean decrease in Gini Index of 3.57[3.09–4.01], higher 
than other non-invasive parameters that may help clinical distinction between the two diseases, namely TAPSE 
and LVEF27, Major Arrhythmic Events (MAE, defined as prior sustained ventricular tachycardia or ventricular 
fibrillation or aborted sudden cardiac death)18, and elevated BNP28. Indeed, miR-320a slightly increased the ACM 
vs. IVT discrimination potentials of the four parameters (Fig. S2).
Assessment of miR-320a association with Arrhythmogenic CardioMyopathy severity. We then 
evaluated whether miR-320a expression was associated with ACM severity. No correlation was found with LVEF 
and TAPSE (Table 3). Similarly, no correlation was found with levels of circulating BNP, a marker of HF previ-
ously associated with RV dysfunction in ACM29. RV low voltage areas at electroanatomic mapping identifies 
fibro-fatty substitution in ACM30; in particular, unipolar mapping allows detection of epicardial pathological 
involvement31. miR-320a plasmatic expression was not associated with low potentials areas of the RV measured 
neither by bipolar nor unipolar mapping (Table 3). In addition, no difference in miR-320a plasmatic expression 
was observed when comparing patients with or without history of MAE, as reported in Table 4. Finally, ACM 
patients were arbitrarily categorized as affected by either severe or mild disease based on the presence or absence 
(at imaging) of ventricular dilation and bulging: again, miR-320a did not show any difference in expression 
between the two groups (Table 4).
Discussion
The diagnostic flowchart for the assessment of ACM could decisively benefit from the discovery and exploitation 
of non-invasive biomarkers. Since circulating miRNAs are cheap, safe, and readily accessible, they represent good 
candidates to be investigated. To date, no study sought an association between circulating miRNAs and ACM. 
In the present work, we report, for the first time, that a plasma miRNA signature may help in ACM diagnosis. 
Specifically, we observed that miR-320a plasma levels are significantly lower in ACM patients compared to both 
HC and IVT patients. Moreover, plasma levels of miR-320a were not influenced by intense physical activity, 
which is known to influence ACM disease penetrance2, as they did not change in athletes, neither in the HC nor 
in the ACM groups. Thus, we may speculate that miR-320a differential expression is independent from increased 
mechanical stretch and training-induced adaptive heart remodelling.
Figure 3. miR-320a plasmatic expression is not influenced by athletic lifestyle. Plasmatic relative expression 
of miR-320a in non-athlete Healthy Controls (HC; n = 36), athlete HC (n = 17), non-athlete Arrhythmogenic 
CardioMyopathy patients (ACM; n = 23), and athlete ACM patients (n = 13). Results are shown with respect 
to the mean expression of miR-320a in non-athlete HC, arbitrarily set to one. Kruskal-Wallis followed by 
Dunns test was used to determine that no significant difference is observed between non-athlete and athlete 
HC subgroups (1.00 ± 0.22 vs. 1.16 ± 0.13; p = 0.10) and between non-athlete and athlete ACM subgroups 
(0.57 ± 0.04 vs. 0.55 ± 0.07; p = 0.60). HC vs. ACM differences are confirmed both between the non-athlete 
(1.00 ± 0.22 vs. 0.57 ± 0.04; p = 0.05) and athlete (1.16 ± 0.13 vs. 0.55 ± 0.07; p < 0.01) subgroups.
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Figure 4. miR-320a shows a lower plasmatic expression in Arrhythmogenic CardioMyopathy (ACM) patients 
when compared to patients affected by Idiopathic Ventricular Tachycardia (IVT). Plasma relative expression of 
miR-320a, in ACM patients (n = 36), with respect to mean expression in IVT patients (n = 21), arbitrarily set to 
one. (IVT 1 ± 0.10; ACM 0.78 ± 0.05; p = 0.03, Mann-Whitney).
Variables n ρ p
LVEF 35 −0.25 0.16
TAPSE 35 −0.32 0.07
BNP 32 −0.20 0.29
Bipolar scar area 17 0.07 0.78
Unipolar scar area 17 −0.05 0.84
Table 3. miR-320a expression does not correlate with continuous variables associated to Arrhythmogenic 
CardioMyopathy (ACM) severity. LVEF, Left Ventricular Ejection Fraction; TAPSE, Tricuspid Annular Plane 
Systolic Excursion; BNP, Brain Natriuretic Peptide; Bipolar Scar Area, percentage of right ventricle non-
conductive (<1.5 mV) area obtained by bipolar analysis of electroanatomic mapping on right ventricle total 
area; Unipolar Scar Area, percentage of right ventricle non-conductive (<5.5 mV) area obtained by unipolar 
analysis of electroanatomic mapping on right ventricle total area. For each variable the Spearman’s rank 
correlation coefficient (ρ) and its statistical significance (p) are reported.
MAE+ MAE− p
n 24 12
miR-320a 0.35 ± 0.03 0.42 ± 0.05 0.22
Severe ACM (imaging) Mild ACM (imaging) p
n 11 18
miR-320a 0.31 ± 0.04 0.37 ± 0.03 0.16
Table 4. miR-320a expression does not vary in subgroups defined by categorical variables associated with 
Arrhythmogenic CardioMyopathy (ACM) severity. MAE+, patients presenting with a history of Major Arrhythmic 
Events; MAE−, patients not presenting history of MAE; miR-320a, relative expression levels showed as mean 
fold change ± SEM (calculated with respect to HC). Severe/Mild ACM (imaging), patients presenting severe or 
mild ventricular impairment, respectively (defined as absence of ventricular dilation and/or bulging at cardiac 
echocardiography or magnetic resonance imaging). For each variable the p-value of the Fisher’s exact test is reported.
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The correct early distinction of a life-threatening condition such as ACM from a benign condition such as 
IVT remains a challenging task. The miR-320a significant differential expression and its high ranking among 
known ACM diagnostic criteria in distinguishing ACM from IVT suggest that this microRNA has the poten-
tial to be clinically exploited for differential diagnosis. Indeed, the classification accuracy of selected established 
ACM diagnostic criteria is improved by the contribution of miR-320a. In addition, miR-320a performed better 
in discriminating ACM vs. IVT than additional non-invasive clinical parameters such as TAPSE, MAE, LVEF, 
and BNP levels.
Considering that clinical ACM diagnosis is challenging particularly in the initial, concealed phase, new tools, 
independent from disease progression, are currently needed. Since we could not detect any correlation between 
miR-320a expression and indexes of ACM severity, we expect that miR-320a could be used as a marker of disease 
presence also at its onset. Indeed it would be interesting to test its diagnostic ability to discriminate patients with 
early-stage ACM from those with ventricular arrhythmias not bound to develop structural defects.
It will be of interest to address, in future studies, any mechanistic role of miR-320a in ACM pathogenesis. 
Intriguingly, miR-320a was found increased during adipogenic differentiation of human mesenchymal bone mar-
row cells32. Moreover, miR-320a expression regulates cardiomyocyte survival33 and the WNT pathway by directly 
targeting β-catenin34, which are both involved in ACM pathogenesis4. In a previous study conducted by screening 
cardiac autopsy samples, 21 miRNAs were selected from all those putatively dysregulated, and were validated as 
being differentially expressed between ACM and HC23. Although miR-320a expression was not investigated, its 
regulation cannot be excluded. Thus, we speculate that our findings in plasma could mirror deregulation in cellu-
lar miR-320a expression, resulting in cardiac cell apoptosis and adipogenesis.
Some study limitations have to be acknowledged. First, the low samples size used for the screening may 
have influenced the results in terms of number of miRNAs identified as putatively regulated. Nevertheless, the 
Figure 5. Importance of non-invasive ACM established diagnostic variables and miR-320a in Arrhythmogenic 
CardioMyopathy (ACM) vs. Idiopathic Ventricular Tachycardia (IVT) classification. (A) Boxplots show the 
distribution of mean decreases in Gini index for non-invasive ACM diagnostic criteria and miR-320a (green 
boxplot), ranked based on the importance in data partition as calculated by the Random Forests procedure. 
Data are shown as median[Q1–Q3]: global/regional dysfunction and structural alteration, 5.75[5.40–6.39]; 
miR-320a, 2.72[2.43–3.12]; arrhythmias, 2.45[2.10–2.79]; repolarization abnormalities, 2.17[1.68–2.59]; 
depolarization abnormalities, 2.03[1.65–2.38]; family history, 0.66[0.48–0.86]. (B) The Area Under the Curves 
(AUC) of the ROC analysis was used to evaluate diagnostic accuracy of selected variables used to classify ACM 
vs. IVT patients and the added value by circulating miR-320a expression. ECG abnormalities: depolarization 
and repolarization abnormality criteria.
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subsequent validation in a consistent number of patients (given the low prevalence of the disease) confirmed the 
soundness of the identified dysregulation. In addition, due to the low ACM occurrence in females, we enrolled 
male patients only. Thus, transferability of our results to the female ACM population should be evaluated in fur-
ther studies. Moreover, as a genetic characterization was not available for most of the recruited patients, a link 
between miR-320a expression and a specific genetic variant could not be addressed in this study. Finally, we did 
not investigate the ACM-specificity of miR-320a expression versus other cardiomyopathies or channelopathies. 
However, these conditions are generally not in the front line for differential diagnosis.
In conclusion, this is the first study addressing the involvement of circulating miRNAs in ACM. The present 
results pave the way to future prospective studies aimed at defining the predictive value of miR-320a in larger 
ACM patients’ cohorts and represent the proof of concept that plasmatic miRNAs could be exploited as potential 
non-invasive biomarkers of ACM diagnosis.
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